Scientific Advisory Board
The Scientific Advisory Board (SAB) comprises experts in oncology, immunology, protein engineering, drug discovery and development.The SAB provides strategic and scientific counsel to IGI’s management and research & development team to help advance the company’s proprietary BEAT® platform and multispecifics directed at blood cancers and solid tumors.
Adam Cohen, M.D.
Dr. Cohen is a graduate of Harvard University. He received his medical degree and residency training from University of Pennsylvania, and completed his hematology/medical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York. Dr. Cohen has lectured frequently and has been widely published in journals and book chapters on the areas of cancer immunotherapy and multiple myeloma.
Adam Cohen, M.D.
Dr. Cohen is a graduate of Harvard University. He received his medical degree and residency training from University of Pennsylvania, and completed his hematology/medical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York. Dr. Cohen has lectured frequently and has been widely published in journals and book chapters on the areas of cancer immunotherapy and multiple myeloma.
Adam Cohen, M.D.
Dr. Cohen is a graduate of Harvard University. He received his medical degree and residency training from University of Pennsylvania, and completed his hematology/medical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York. Dr. Cohen has lectured frequently and has been widely published in journals and book chapters on the areas of cancer immunotherapy and multiple myeloma.
Wolf Hervé Fridman, M.D., Ph.D.
Professor Emeritus of Immunology, at Université Paris Cité Medical School, France
Dr. Fridman’s focus is on the role the immune system plays in the control of human malignancies and he is world-renowned in the area of tumor immunology.
Wolf Hervé Fridman, M.D., Ph.D.
Professor Emeritus of Immunology, at Université Paris Cité Medical School, France
Dr. Fridman’s focus is on the role the immune system plays in the control of human malignancies and he is world-renowned in the area of tumor immunology.
Wolf Hervé Fridman, M.D., Ph.D.
Professor Emeritus of Immunology, at Université Paris Cité Medical School, France
Dr. Fridman’s focus is on the role the immune system plays in the control of human malignancies and he is world-renowned in the area of tumor immunology.
Sergio Giralt, M.D.
Professor of Medicine, Deputy Division Head of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center, USA
Dr. Giralt’s clinical research focus is on stem cell transplantation for patients with blood disorders. He trained and worked at the University of Texas M.D. Anderson Cancer Center, where he was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, Dr. Giralt joined the faculty of Memorial Sloan-Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service and served as Chief until February 2020.
Sergio Giralt, M.D.
Professor of Medicine, Deputy Division Head of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center, USA
Dr. Giralt’s clinical research focus is on stem cell transplantation for patients with blood disorders. He trained and worked at the University of Texas M.D. Anderson Cancer Center, where he was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, Dr. Giralt joined the faculty of Memorial Sloan-Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service and served as Chief until February 2020.
Sergio Giralt, M.D.
Professor of Medicine, Deputy Division Head of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center, USA
Dr. Giralt’s clinical research focus is on stem cell transplantation for patients with blood disorders. He trained and worked at the University of Texas M.D. Anderson Cancer Center, where he was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies. In May 2010, Dr. Giralt joined the faculty of Memorial Sloan-Kettering Cancer Center to lead the Adult Bone Marrow Transplant Service and served as Chief until February 2020.
Lawrence Olanoff, M.D., Ph.D.
Director, Ichnos Sciences, Adjunct Assistant Professor and Special Advisor to the President for Corporate Relations at the Medical University of South Carolina, USA
Dr. Olanoff previously served as President and Chief Operating Officer for Forest Laboratories, Inc., and Chief Executive Officer of Celsion Corporation. During his career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals across several therapeutic areas. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University and has authored forty scientific publications on topics including drug delivery, pharmacokinetics and drug metabolism.
Lawrence Olanoff, M.D., Ph.D.
Director, Ichnos Sciences, Adjunct Assistant Professor and Special Advisor to the President for Corporate Relations at the Medical University of South Carolina, USA
Dr. Olanoff previously served as President and Chief Operating Officer for Forest Laboratories, Inc., and Chief Executive Officer of Celsion Corporation. During his career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals across several therapeutic areas. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University and has authored forty scientific publications on topics including drug delivery, pharmacokinetics and drug metabolism.
Lawrence Olanoff, M.D., Ph.D.
Director, Ichnos Sciences, Adjunct Assistant Professor and Special Advisor to the President for Corporate Relations at the Medical University of South Carolina, USA
Dr. Olanoff previously served as President and Chief Operating Officer for Forest Laboratories, Inc., and Chief Executive Officer of Celsion Corporation. During his career, Dr. Olanoff made substantial contributions leading to thirty new drug approvals across several therapeutic areas. He received his Ph.D. in biomedical engineering and M.D. degree from Case Western Reserve University and has authored forty scientific publications on topics including drug delivery, pharmacokinetics and drug metabolism.
Kumar Prabhash, M.D.
Head Solid Tumors Unit, Medical Oncology, Tata Memorial Hospital, Mumbai, India
Dr. Kumar Prabhash is a well-known Medical Oncologist with over 20 years of experience currently working at Tata Memorial Hospital, Mumbai as Head Solid Tumors Unit, Medical Oncology. Dr. Prabhash specializes in medical oncology, lung cancer, and head and neck tumor. He has worked on more than 80 projects and has extensive experience in in conducting cancer-related trials and research. He has published more than 100 research papers in Indian and international medical journals.
Kumar Prabhash, M.D.
Head Solid Tumors Unit, Medical Oncology, Tata Memorial Hospital, Mumbai, India
Dr. Kumar Prabhash is a well-known Medical Oncologist with over 20 years of experience currently working at Tata Memorial Hospital, Mumbai as Head Solid Tumors Unit, Medical Oncology. Dr. Prabhash specializes in medical oncology, lung cancer, and head and neck tumor. He has worked on more than 80 projects and has extensive experience in in conducting cancer-related trials and research. He has published more than 100 research papers in Indian and international medical journals.
Kumar Prabhash, M.D.
Head Solid Tumors Unit, Medical Oncology, Tata Memorial Hospital, Mumbai, India
Dr. Kumar Prabhash is a well-known Medical Oncologist with over 20 years of experience currently working at Tata Memorial Hospital, Mumbai as Head Solid Tumors Unit, Medical Oncology. Dr. Prabhash specializes in medical oncology, lung cancer, and head and neck tumor. He has worked on more than 80 projects and has extensive experience in in conducting cancer-related trials and research. He has published more than 100 research papers in Indian and international medical journals.
Eugene Zhukovsky, Ph.D.
Manager and Partner, ZM Scientific, Switzerland
Dr. Zhukovsky served as the Chief Scientific Officer of Ichnos, Affimed and Biomunex Pharmaceuticals and as the Chief Technology Officer of Go Therapeutics. Dr. Zhukovsky has extensive experience in progression of drug candidates from discovery to clinic and led development of novel technologies with a particular focus on immuno-oncology and T cell redirecting platforms. He was the early lead discoverer of Monjuvi®, an anti-CD19 antibody against lymphoma. Dr. Zhukovsky has authored numerous scientific articles and is listed as a co-inventor on more than 15 granted patents and applications. He was previously named as one of the top 50 Global Antibody Industry Influencers.
Eugene Zhukovsky, Ph.D.
Manager and Partner, ZM Scientific, Switzerland
Dr. Zhukovsky served as the Chief Scientific Officer of Ichnos, Affimed and Biomunex Pharmaceuticals and as the Chief Technology Officer of Go Therapeutics. Dr. Zhukovsky has extensive experience in progression of drug candidates from discovery to clinic and led development of novel technologies with a particular focus on immuno-oncology and T cell redirecting platforms. He was the early lead discoverer of Monjuvi®, an anti-CD19 antibody against lymphoma. Dr. Zhukovsky has authored numerous scientific articles and is listed as a co-inventor on more than 15 granted patents and applications. He was previously named as one of the top 50 Global Antibody Industry Influencers.
Eugene Zhukovsky, Ph.D.
Manager and Partner, ZM Scientific, Switzerland
Dr. Zhukovsky served as the Chief Scientific Officer of Ichnos, Affimed and Biomunex Pharmaceuticals and as the Chief Technology Officer of Go Therapeutics. Dr. Zhukovsky has extensive experience in progression of drug candidates from discovery to clinic and led development of novel technologies with a particular focus on immuno-oncology and T cell redirecting platforms. He was the early lead discoverer of Monjuvi®, an anti-CD19 antibody against lymphoma. Dr. Zhukovsky has authored numerous scientific articles and is listed as a co-inventor on more than 15 granted patents and applications. He was previously named as one of the top 50 Global Antibody Industry Influencers.
Carlos Garcia-Echeverria, Ph.D
Drug Discovery Scientist, Pharma Executive, Cancer Research Horizons
Dr Garcia-Echeverria is a distinguished figure in the pharmaceutical and biotech industries, with a broad range of expertise in drug discovery, early-stage clinical development and strategic leadership. His career spans across biotech and major companies, including EQRx, Sanofi and Novartis, where he has significantly contributed to advancing innovative therapies across various disease areas and modalities. His research work is well-recognized, with 190 peer-reviewed publications and 45 granted patents, marking his influence in the scientific community. Currently, as a scientific and strategic advisor to BioPharma and Venture Capital firms, Dr. Garcia-Echeverria continues to shape the future of the biopharma industry by advising on drug discovery projects, development strategies and partnerships.
Carlos Garcia-Echeverria, Ph.D
Drug Discovery Scientist, Pharma Executive, Cancer Research Horizons
Dr Garcia-Echeverria is a distinguished figure in the pharmaceutical and biotech industries, with a broad range of expertise in drug discovery, early-stage clinical development and strategic leadership. His career spans across biotech and major companies, including EQRx, Sanofi and Novartis, where he has significantly contributed to advancing innovative therapies across various disease areas and modalities. His research work is well-recognized, with 190 peer-reviewed publications and 45 granted patents, marking his influence in the scientific community. Currently, as a scientific and strategic advisor to BioPharma and Venture Capital firms, Dr. Garcia-Echeverria continues to shape the future of the biopharma industry by advising on drug discovery projects, development strategies and partnerships.
Carlos Garcia-Echeverria, Ph.D
Drug Discovery Scientist, Pharma Executive, Cancer Research Horizons
Dr Garcia-Echeverria is a distinguished figure in the pharmaceutical and biotech industries, with a broad range of expertise in drug discovery, early-stage clinical development and strategic leadership. His career spans across biotech and major companies, including EQRx, Sanofi and Novartis, where he has significantly contributed to advancing innovative therapies across various disease areas and modalities. His research work is well-recognized, with 190 peer-reviewed publications and 45 granted patents, marking his influence in the scientific community. Currently, as a scientific and strategic advisor to BioPharma and Venture Capital firms, Dr. Garcia-Echeverria continues to shape the future of the biopharma industry by advising on drug discovery projects, development strategies and partnerships.
Philippe Moreau, MD, PhD
Serves as Professor of Clinical Hematology at the University Hospital of Nantes at the Medical University of Nantes in France
Professor Moreau is a member of the administration council of the Intergroupe Francophone du Myélome (IFM) which he chaired from 2006 through 2009. He is also a member of the International Myeloma Working Group (IMWF) and President of the International Myeloma Society (IMS). Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents. He has served as the principal investigator of many international randomized phase 3 clinical trials and his research is widely published.
Professor Moreau has authored or coauthored more than 600 peer-reviewed articles that have appeared in high impact factor journals including the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet Oncology, and Blood. He is a member of the editorial boards of the Journal of Clinical Oncology, Blood, and Blood Cancer Journal and is frequently invited to speak at international hematologic oncology meetings.”
Philippe Moreau, MD, PhD
Serves as Professor of Clinical Hematology at the University Hospital of Nantes at the Medical University of Nantes in France
Professor Moreau is a member of the administration council of the Intergroupe Francophone du Myélome (IFM) which he chaired from 2006 through 2009. He is also a member of the International Myeloma Working Group (IMWF) and President of the International Myeloma Society (IMS). Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents. He has served as the principal investigator of many international randomized phase 3 clinical trials and his research is widely published.
Professor Moreau has authored or coauthored more than 600 peer-reviewed articles that have appeared in high impact factor journals including the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet Oncology, and Blood. He is a member of the editorial boards of the Journal of Clinical Oncology, Blood, and Blood Cancer Journal and is frequently invited to speak at international hematologic oncology meetings.”
Philippe Moreau, MD, PhD
Serves as Professor of Clinical Hematology at the University Hospital of Nantes at the Medical University of Nantes in France
Professor Moreau is a member of the administration council of the Intergroupe Francophone du Myélome (IFM) which he chaired from 2006 through 2009. He is also a member of the International Myeloma Working Group (IMWF) and President of the International Myeloma Society (IMS). Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents. He has served as the principal investigator of many international randomized phase 3 clinical trials and his research is widely published.
Professor Moreau has authored or coauthored more than 600 peer-reviewed articles that have appeared in high impact factor journals including the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet Oncology, and Blood. He is a member of the editorial boards of the Journal of Clinical Oncology, Blood, and Blood Cancer Journal and is frequently invited to speak at international hematologic oncology meetings.”